Regional Signature Matrix

The Regional Signature Matrix defines the unique anatomical identity of each SIRIAM formulation.

While all formulations share the same Clinical Architecture, Vehicle Architecture, Structural Matrix and Functional Matrix, each regional formulation possesses its own Regional Signature Matrix.

The Regional Signature Matrix specifies:

the conceptual formulation objective within the SIRIAM Platform.

It therefore represents the distinguishing identity of each formulation while preserving overall platform consistency.

• the anatomical focus;
• the neurodermal target region;
• the principal Application Field;
• the standardized Neurodermal Application Zones (NAZ);

Every regional formulation follows an identical design hierarchy.

Platform Standards

↓

Clinical Architecture

↓

Metameric Foundation

↓

Application Field

↓

Functional Matrix

↓

Regional Signature Matrix

↓

Final Pharmaceutical Formulation

Only the Regional Signature Matrix changes between formulations.

Primary Application Field

Occipito-Atlanto-Axial Complex

Anatomical Focus

Cranio-cervical junction

Suboccipital region

Upper cervical neurodermal network

Transition between skull and cervical spine

Standardized Neurodermal Application Zones

Suboccipital

Retroauricular

Submandibular

Pre-SCM

Regional Design Philosophy

The OAA formulation represents the cranial gateway of the SIRIAM Platform.

It is designed around the neurodermal integration of the upper cervical region and serves as the superior entry point of the metameric recovery architecture.

Regional Signature Matrix

The Regional Signature Matrix of OAA is selected to support the intended functional identity of the cranio-cervical Application Field while remaining compatible with the standardized platform architecture.

Primary Application Field

Anterior Cervical Transition

Anatomical Focus

C3–C5 region

Anterior cervical fascia

Phrenic nerve projection

Cervical respiratory transition

Design Philosophy

The Phrenic formulation represents the transitional region between the cranio-cervical and cervico-thoracic Application Fields.

Its architecture is optimized for the anterior cervical neurodermal interface.

Primary Application Field

Cervico-Brachial Transition

Anatomical Focus

C5–T1

Brachial plexus projection

Shoulder girdle

Proximal upper limb

Design Philosophy

The Plexus Brachialis formulation establishes the neurodermal transition from the cervical spine toward the upper extremity.

It forms the principal regional interface between spinal and peripheral neurodermal architecture.

Primary Application Field

Cervico-Thoracic Transition

Anatomical Focus

Lower cervical spine

Upper thoracic junction

Cervico-thoracic transition

Design Philosophy

The CTO formulation bridges the cranial platform with the thoracic neurodermal architecture.

It maintains continuity between cervical and thoracic regional Application Fields.

Primary Application Field

Upper Abdominal Neurodermal Field

Anatomical Focus

T5–T9

Epigastric region

Solar plexus projection

Upper abdominal neurodermal interface

Design Philosophy

The Plexus Solaris formulation represents the central neurodermal integration field of the trunk.

Within the SIRIAM Platform it functions as the principal upper abdominal regional interface.

Primary Application Field

Thoraco-Lumbar Transition

Anatomical Focus

T10–L2

Thoracolumbar junction

Lumbar transition zone

Design Philosophy

The TLO formulation connects thoracic and lumbar neurodermal architecture while maintaining continuity of the regional platform.

Primary Application Field

Lumbar Neurodermal Field

Anatomical Focus

Lumbar plexus projection

L1–L4 region

Anterior lumbar neurodermal interface

Design Philosophy

The Plexus Lumbalis formulation extends the thoracolumbar architecture toward the lower extremity through the lumbar neurodermal network.

Primary Application Field

Lumbo-Sacral Transition

Anatomical Focus

L4–S2

Lumbosacral plexus projection

Pelvic transition

Design Philosophy

The formulation represents the transition between lumbar and sacral neurodermal architecture.

Primary Application Field

Sacral Neurodermal Field

Anatomical Focus

Sacrum

Coccygeal transition

Pelvic neurodermal interface

Design Philosophy

SX represents the caudal completion of the metameric recovery platform.

It serves as the inferior counterpart of the OAA formulation.

Together they define the superior and inferior boundaries of the neurodermal axis.

Functional Identity

KORR Integralis differs fundamentally from the regional formulations.

It is not assigned to a regional Application Field.

Instead, it functions as the standardized segmental formulation for isolated facilitated dermatomes or spinal segments.

Design Philosophy

KORR is intended as a focused segmental application within the overall platform.

It complements, but does not replace, the regional architecture.

Functional Identity

InflammaSacra is not part of the metameric recovery line.

It constitutes the symptom- and phase-oriented support platform.

Platform Position

InflammaSacra may accompany regional formulations when clinically indicated but maintains an independent formulation philosophy.

Its progression follows:

Phase I

Phase II

Phase III

rather than the regional DUO architecture.

Although each formulation possesses a distinct Regional Signature Matrix, all remain integrated within the same platform architecture.

Regional diversity therefore represents specialization rather than fragmentation.

Every formulation contributes to one coherent neurodermal treatment platform.

The modular architecture of the Regional Signature Matrix allows the future addition of new regional formulations without modification of the existing platform structure.

Any new formulation shall:

undergo pharmaceutical validation prior to release.

Professional Review Notes (Anouck Van Aerschot)

Review 14.1 – Regionale identiteit

☐ Controleren of de formuleringen voldoende onderscheidend zijn binnen dezelfde platformarchitectuur.

☐ Evalueren of de regionale signatuur farmacotechnisch ondersteund wordt.

Review 14.2 – Ingrediënttoewijzing

☐ Bevestigen dat elke Regionale Signatuur coherent vertaald wordt naar de uiteindelijke magistrale samenstelling.

☐ Eventuele overlap of redundantie tussen regionale ingrediënten beoordelen.

Review 14.3 – Platformconsistentie

☐ Nagaan of wijzigingen aan één formulering geen ongewenste impact hebben op de coherentie van het totale platform.

☐ Harmonisatievoorstellen documenteren in de Development Record.

Review 14.4 – Productportfolio

☐ Bevestigen dat elke regionale formulering een duidelijke plaats heeft binnen de totale neurodermale as.

☐ Toekomstige uitbreidingen toetsen aan de Platform Standards.

✦ Editor's R&D Note (werkversie)

Dit hoofdstuk beschrijft bewust de identiteit van elke productlijn en niet de definitieve ingrediëntenlijsten. De uiteindelijke magistrale samenstellingen worden afzonderlijk beheerd in de Master Formula's en kunnen tijdens de ontwikkelingscyclus worden aangepast zonder de regionale ontwerpfilosofie te wijzigen.

• comply with the Platform Standards;
• possess a clearly defined Application Field;
• follow the standardized Clinical and Functional Architecture;
• define its own Regional Signature Matrix;